Fallopian Tube Cancer Clinical Trials

Recruiting

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

NCT06824467

Conditions: Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +17 more
Locations: University of Alabama at Birmingham ( Site 0006) Birmingham, Alabama, United States

Alaska Women's Cancer Care ( Site 0096) Anchorage, Alaska, United States

UCSF Medical Center at Mission Bay ( Site 0013) San Francisco, California, United States

John Muir Health Cancer Center ( Site 0016) Walnut Creek, California, United States

View all 196 locations

View Trial Details

Recruiting

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

NCT06890338

Conditions: Adnexal Diseases, Carcinoma, Carcinoma, Ovarian Epithelial, +22 more
Locations: University of Alabama at Birmingham (UAB) Hospital /ID# 274793 Birmingham, Alabama, United States

Usa Mitchell Cancer Institute /ID# 276022 Mobile, Alabama, United States

University of California Los Angeles Medical Center /ID# 274566 Los Angeles, California, United States

Scripps Md Anderson - Prebys Cancer Center /ID# 276891 San Diego, California, United States

View all 69 locations

View Trial Details

Recruiting

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

NCT05281471

Conditions: Adnexal Diseases, DNA Virus Infections, Endocrine Gland Neoplasms, +26 more
Locations: The University of South Alabama, Mitchell Cancer Institute Mobile, Alabama, United States

University of Arizona Cancer Center Tucson, Arizona, United States

City of Hope Duarte, California, United States

UC San Diego Health - Moores Cancer Center La Jolla, California, United States

View all 33 locations

View Trial Details

Recruiting

A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab

NCT04590326

Conditions: Adnexal Diseases, Disease Attributes, Endocrine Gland Neoplasms, +25 more
Locations: City of Hope Comprehensive Cancer Center Duarte, California, United States

The City of Hope Orange County Lennar Foundation Cancer Center Irvine, California, United States

Chao Family Comprehensive Cancer Center Orange, California, United States

H. Lee Moffitt Cancer Center Tampa, Florida, United States

View all 28 locations

View Trial Details

Recruiting

A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors

NCT06792552

Conditions: Adenocarcinoma, Adnexal Diseases, Advanced Solid Tumors, +35 more
Locations: Sarah Cannon Research Institute (SCRI) - Lake Nona Orlando, Florida, United States

Emory Winship Cancer Institute Atlanta, Georgia, United States

University Medical Center of New Orleans LSU-LCMC Health Cancer Center New Orleans, Louisiana, United States

Dana-Farber Cancer Institute Boston, Massachusetts, United States

View all 17 locations

View Trial Details

Recruiting

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

NCT06787612

Conditions: Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +17 more
Locations: The University of Alabama at Birmingham Birmingham, Alabama, United States

UC San Diego Health La Jolla, California, United States

Cedars Sinai Medical Center Los Angeles, California, United States

Mayo Clinic Jacksonville Jacksonville, Florida, United States

View all 55 locations

View Trial Details

Recruiting

Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT05739981

Conditions: Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +17 more
Locations: Johns Hopkins Medicine SKCCC Baltimore, Maryland, United States

Memorial Sloan Kettering Cancer Center New York, United States

OU Health, Stephenson Cancer Center Oklahoma City, Oklahoma, United States

University of Texas MD Anderson Cancer Center Houston, Texas, United States

View Trial Details

Recruiting

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

NCT05579366

Conditions: Adenoma, Adnexal Diseases, Breast Adenocarcinoma, +49 more
Locations: USOR HonorHealth Phoenix, Arizona, United States

USOR Arizona Oncology Associates Tucson, Arizona, United States

University of California Los Angeles Medical Center Los Angeles, California, United States

University of California, San Diego; Moores Cancer Center San Diego, California, United States

View all 66 locations

View Trial Details

Recruiting

Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer

NCT06915025

Conditions: Adnexal Diseases, Carcinoma, Carcinoma, Ovarian Epithelial, +22 more
Locations: Advent Health Orlando, Florida, United States

Masonic Cancer Center, University of Minnesota Minneapolis, Minnesota, United States

Washington University School of Medicine in St. Louis St Louis, Missouri, United States

Providence Cancer Institute Portland, Oregon, United States

View Trial Details

Recruiting

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

NCT04657068

Conditions: Acinar Cell Carcinoma, Adenocarcinoma, Adnexal Diseases, +55 more
Locations: University of Alabama at Birmingham Birmingham, Alabama, United States

Mayo Clinic (Arizona) Scottsdale, Arizona, United States

University of Arkansas - Winthrop P. Rockefeller Cancer Institute Little Rock, Arkansas, United States

USC Norris Comprehensive Cancer Center Los Angeles, California, United States

View all 82 locations

View Trial Details

Fallopian Tube Cancer

Fallopian Tube Cancer trial results

Related conditions